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Imaging dose in radiation therapy has traditionally been ignored due to its low magnitude and frequency
in comparison to therapeutic dose used to treat patients. The advent of modern, volumetric, imaging
modalities, often as an integral part of linear accelerators, has facilitated the implementation of image-
guided radiation therapy (IGRT), which is often accomplished by daily imaging of patients. Daily imaging
results in additional dose delivered to patient that warrants new attention be given to imaging dose. This
review summarizes the imaging dose delivered to patients as the result of cone beam computed to-
mography (CBCT) imaging performed in radiation therapy using current methods and equipment. This
review also summarizes methods to calculate the imaging dose, including the use of Monte Carlo (MC)
and treatment planning systems (TPS). Peripheral dose from CBCT imaging, dose reduction methods, the
use of effective dose in describing imaging dose, and the measurement of CT dose index (CTDI) in CBCT
systems are also reviewed.
© 2015 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cone beam computed tomography (CBCT) was developed in late
1990s and put into clinical use in radiation therapy in the early
2000s. A CBCT system utilizes either the Megavoltage radiation
beam delivered from the linear accelerator (linac), or a kilovoltage
beam delivered using an additional x-ray tube mounted on the
linac, to image the object from multiple projection angles and
reconstruct a 3D image using the projected images. The beneﬁt of
CBCT, as opposed to the traditional 2D imaging using a portal im-
aging device, is volumetric visualization of the patient's body as
well as enhanced visualization of soft tissue.
Due to the superiority of CBCT imaging in patient positioning,
there has been a rapid growth of the use of these systems in radi-
ation therapy, which has helped to make image-guided radiation
therapy a routine technique employed worldwide. Currently, a
variation of CBCT imaging is employed in Varian (Varian Medical
Systems, Palo Alto, USA), Elekta (Elekta AB Stockholm, Sweden),
Siemens (Siemens AG, Erlangen, Germany), andmore recently, Vero
(Brainlab AG, Feldkirchen, Germany) radiation delivery units.ica. Published by Elsevier Ltd. ThisProfessional societies have recognized the growing use of this
technology in routine clinical care and published guidelines for
implementation and use of these systems. Among these are the
“ACReASTRO Practice Guidelines for Image-Guided Radiation
Therapy (IGRT)” [1], the “National Radiotherapy Implementation
Group Report on Image Guided Radiotherapy (IGRT)” [2]published
by the United Kingdom's National Cancer Programme Initiative,
and the ASTRO white paper “Safety considerations for IGRT” [3].
Furthermore, there is recent indication that the use of IGRT may
improve the clinical outcome of patients undergoing radiation
therapy, which reinforces the use of image guidance [4].
The imaging dose delivered to patients from CBCT became an
issue of concern soon after the start of clinical utilization of these
systems. Even though imaging has been used for patient posi-
tioning since the onset of radiation therapy, the increased (often
daily) frequency of imaging in the era of IGRT, as opposed to the
traditional weekly portal imaging, and the potential inclusion of
larger volumes of normal structures in CBCT, raises the quantity of
the dose delivered to the patient from imaging, as well as the in-
tegral dose. There is also the additional concern of increasing the
chance of secondary cancers because of imaging dose. These sto-
chastic risks have been recognized and estimated by the American
Association of Physicists in Medicine (AAPM) Task Group 75 [5] and
others [6,7]. Realizing the potential for signiﬁcant imaging dose,is an open access article under the CC BY-NC-ND license (http://creativecommons.
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ments and calculations. The distribution of papers published on
imaging dose from CBCT per year is shown in Fig. 1. This ﬁgure only
includes papers in peer-reviewed publications with complete
methods and results sections.
In addition to the absorbed dose from CBCT, the use of different
quality beams other than the therapeutic megavoltage ones raises
questions as to themagnitude of effective dose delivered to patient,
and the utilization of kilovoltage beams results in increased dose to
the bones relative to soft tissue, which may be of concern in im-
aging of pediatric patients.
The availability and growing use of CBCT in radiation therapy
has resulted in a large volume of publications in this ﬁeld. In a
previous publication Sykes [8] et al. reported on typical doses from
commercial CBCT systems as well as on clinical consequences (risks
and beneﬁts) of using CBCT based IGRT. Although that work
compiled useful data, it was not designed as a literature review. The
aim of this systematic review was to ﬁnd, categorize and summa-
rize all high quality research data onmeasurements and calculation
of the dose from CBCT imaging for both kilovoltage and Mega-
voltage imaging beams incorporated into radiotherapy linear
accelerators.
There have been over 500 publications since early 2000s that
include terms such as “cone beam CT” or “CBCT” and “radiation
therapy” or “radiotherapy” as a key word, based on the advanced
search performed using the engine Scopus.com (Elsevier B.V., The
Netherlands). This review was conducted by searching the litera-
ture for all the work published on measurement and calculation of
CBCT dose, including collection of beam data, modeling, estimation
of peripheral and effective dose, and strategies to reduce dose. Of
the 500 publications, only those that were relevant for this study,
and included complete data and clear methods and results sections
were included in this review.
Measured and calculated dose values are systematically re-
ported for various systems and acquisition protocols. The variation
of imaging dose with tissue density and body size, peripheral dose,
dose reductionmethods, and effective dose are also included in this
work. The review also includes published data on measurements of
CT Dose Index (CTDI) for CBCT systemswith all the published values
of CTDI methodically tabulated. The CTDI, although not a direct
measure of patient dose, is a very commonly used index and its
inclusion in this reviewwas deemed beneﬁcial for the professionalsFigure 1. The distribution of papers published on measurement or calculation of imaging
search of the Scopus.com bibliographic database.involved in the assessment of CBCT image quality and dose deliv-
ered using different systems and techniques.
This review could serve as a comprehensive source of data
pertaining to various devices and techniques used in radiation
therapy, helping clinicians and physicists with their decisions in
routine clinical practice. The current review does not include in-
formation on the dose from fan-beam CT scanners, whether kilo-
voltage or Megavoltage (i.e. TomoTherapy (Accuray, Madison,
USA)). It also does not include the topic of dose delivered to patients
as a result of CBCT in diagnostic radiology, cardiology, and dentistry.
Recent papers by Kalendar [9] and Dougeni et al. [10] provide a
review of CT imaging doses in diagnostic radiology and other
publications include dose values for Tomotherapy [11,12], C-arm
CBCT [13], dental CBCT [14,15], and 4D CT systems [16].
This review is organized as follows: The ﬁrst two sections focus
on CBCT dose measurement and calculation, covering CBCT imag-
ing dose measurements in phantom and patient, and CBCT imaging
dose calculations, including beam data collection and modeling;
Monte Carlomethods; use of treatment planning systems and other
methods. The following sections review peripheral dose from CBCT
imaging; CBCT imaging dose reduction, with special emphasis on
pediatric cases; and the use of effective dose in CBCT imaging. The
last section covers published data on CTDI measurements for CBCT
systems. Each section consists of relevant data along with a dis-
cussion of the ﬁndings when appropriate.
CBCT imaging dose measurements
Among the papers reporting on dose measurements (excluding
CTDI), 80% present results for phantom measurements and 20%
present patient measurement data. Various detectors such as ion
chamber, thermoluminiscent dosimeter (TLD), metal-
eoxideesemiconductor ﬁeld-effect transistor (MOSFET), radio-
graphic and radiochromic ﬁlm, optically stimulated luminescence
dosimeter (OSLD), and glass dosimeter have been used for this
purpose, many of which produce challenges as to the detector
calibration and response to low energy radiation when used for kV
CBCT dosimetry. This warrants additional investigation into the
suitability of the detector for these types of measurements, an
example of which is the work done for OSLDs [17]. CBCT dose
measurements were divided into two categories: phantom and
patient studies and are summarized below.dose from CBCT in radiation therapy (2005e2014). The data is based on an advanced
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The majority of work done on measuring the dose from CBCT
imaging has been in phantoms for obvious reason of convenience
and availability of them [6,18e44]. Of these, a large number have
used anthropomorphic phantoms and TLDs as dosimeters, and
others employed other types of phantoms and various detectors
such as ion chamber, ﬁlm, MOSFET, and OSLD. A summary of these
can be found in Table 1. The doses measured range from 0.01 to
13 cGy per acquisition due to variations of imaging devices, type
and size of phantom, location of measurement within phantom,
and imaging techniques used. Due to the wide variation of exper-
imental setups, it is hard to assign one value to the dose magnitude
based on the anatomy imaged. In general, for the kilovoltage im-
aging, the low dose values are from head and neck imaging pro-
tocols that employ lower time-current products (mAs) and partial
arc image acquisition whereas the higher ones are from trunk im-
aging with higher mAs values and full 360 image acquisition.
Megavoltage CBCT imaging using the 6MV beam (commonly called
Therapy Beam Line or TBL) results in higher dose than kilovoltage
one with a direct correlation to the imaging protocol (i.e. MU
setting) used. However, the Megavoltage dose is often more evenly
distributed within the body whereas the kilovoltage dose is more
heterogeneously distributed and typically exhibits its maximum
dose on the skin, and with the increased absorption in bone due to
prominence of photoelectric effect.
Patient studies
The patient studies generally employed TLDs or other dosime-
ters to measure skin dose [20e22,27,45] although there have been
two studies measuring the dose inside the rectum [46,47]. Patient
dose measurements are summarized in Table 2. The skin dose
measurements range from fraction of a cGy (for low dose head and
neck imaging) to 7 cGy (for high dose pelvic ones) and vary based
on the measurement location, technique used, and patient size.
These values are in the same range of those measured in phantom
listed in Table 1. The rectal dose measurements indicate 2e3 cGy
average dose to rectum per CBCT acquisition for the protocol
commonly used in clinical practice for pelvic imaging on the Elekta
system.
CBCT imaging dose calculations
Imaging dose calculations often require beam data collection,
modeling of the imaging systems, and veriﬁcation of the accuracy
of the model. In this section, we report on the studies that dealt
with CBCT modeling and dose calculation.
Beam data collection and modeling
Imaging beam data for the kilovoltage units can be measured,
simulated using Monte Carlo (MC) methods and, depending on the
TPS used, modeled in the treatment planning system. Imaging
beam data collection has its own challenges as compared to Meg-
avoltage therapeutic ones as it is often difﬁcult to position a water
scanning system within the unit. Other challenges include low
output of the imaging beams, which produce a low signal at depth
and heating of the x-ray tube. For these reasons, beam data gen-
eration can be the result of a combination of measurements andMC
simulations, with the latter being used to verify the accuracy of
measurements.
MC simulation and veriﬁcation of the imaging beams has been
performed by Ding et al. [48,49]for the Varian On Board Imaging
(OBI) unit, and by Spezi [50] and Downes [51] for the Elekta X-ray
Volume Imaging (XVI) unit, among others. Beam modeling in a
treatment planning system for the OBI unit has been done by Alaeiet al. [52] for the half-bowtie, half-fan acquisition, and by Alaei and
Spezi [53] for most of the XVI imaging presets.
Megavoltage imaging employing the megavoltage treatment
beam (Siemens) requires no beam data collection. As such, the
imaging beam can easily be added to the treatment plans by adding
an arc beam of 6MV photons. This has been done by several groups,
indicating its feasibility and the ability of including MV CBCT dose
in treatment planning [54,55]. The Siemens units, however, have
the capability of cone beam imaging using two other modalities: 1)
An “Imaging Beam Line” or IBL, which employs a degraded 4.2 MeV
Megavoltage beam and a Carbon target to produce the imaging
beam [56] and 2) The kVision kilovoltage imaging beam which
employs a kilovoltage x-ray tube and image detector along the
megavoltage beam line but in a reverse geometry. The IBL beam
data has been collected and modeled in a treatment planning
system by Flynn et al. [45] and similar work has been done by
Dzierma et al. for the kVision system [57]. Table 3 contains a
summary of beam data collection and simulation/modeling papers,
noting that there are other publications in which some beam data
collection is presented.
Monte Carlo methods
The MC method is regarded as a gold standard for modeling
particle tracking and dose deposition in a wide range of energies of
therapeutic and imaging interest. In the ﬁeld of CBCT imaging dose
calculations the EGSnrc code system, which includes the BEAMnrc
and DOSXYZnrc codes, has been extensively used alongside other
general purpose MC codes such as MCNP and Geant4
[48e51,58e71]. All publications found in our literature search re-
ported 3D dose data calculated on voxelised geometries repre-
senting human anatomy, based on patient CT scans or virtual
phantoms. Approximately half of the papers reported the use of
phase space ﬁles generated at the exit window of the CBCT unit for
each collimator setting used for imaging the patient. About 30% of
the papers reported the use of a multiple source model of the CBCT
unit and in the remainder particles were sampled from either a full
simulation of the CBCT beam line (beam model) or using a simple
photon spectrum. The Monte-Carlo studies have been summarized
in Table 4. Due to high number of publications and the amount of
data reported in these papers, it is not feasible to list all the organ
dose data in this review. Hence we report in the dose summary
column in Table 4 a cross-reference to the table number in the
respective publication where the organ dose data can be found.
Use of treatment planning system and other methods
Computing and adding imaging dose to therapeutic one pro-
duces a complete picture of dose distribution in patient. This is
easily achievable for imaging systems that utilize the therapeutic
beam for imaging such as Megavoltage portal imaging and cone
beam CT, even though this was never a routine practice in the era of
port ﬁlms and electronic portal imaging. Megavoltage cone beam
CT adds considerable amount of dose to the treatment volume and
surrounding tissue, hence its inclusion in the treatment plan was
suggested early on andmultiple papers report the dose to phantom
and patient from MV CBCT imaging using different dose settings
[23,24,28,54,73e76]. Similar work was performed for the imaging
dose from Siemens IBL system, and compared to that of the original
6 MV imaging beam (TBL) [45,77].
Inclusion of kilovoltage imaging beam in the treatment plan,
however, requires beam data collection and modeling. Some of the
work done in this area is listed in Table 3, which only applies to
Pinnacle treatment planning system (Philips Medical Systems,
Milpitas, CA) used for imaging beam modeling and dose
Table 1
Summary of CBCT dose measurements in phantom. The version of the imaging system is only included when available.
Kilovoltage
CBCT
Manufacturer (Version,
if speciﬁed)
kVp mAs/acquisition Phantom type Dosimeter Dose in phantom/
fraction (cGy)
Sykes [18] Elekta XVI (v3.1) 130 0.56 Rando head TLD 1.9e2.9
Islam [20] Elekta XVI 100 2 Cylindrical (16 & 30 cm dia.) Chamber 0.7e3.5
120 2
140 2
Amer [21] Elekta XVI 100 0.1 Rando head TLD 0.13
120 0.4 Rando chest 0.72
130 1.2 Rando pelvis 2.1
Wen [22] Varian OBI 125 2 Rando pelvis TLD 2.1e4.7
Kan [6] Varian OBI 125 2 Female Rando head, chest, pelvis TLD 3.6e6.7
125 0.4
Osei [25] Varian OBI 125 2 Rando pelvis TLD 3.0e11.5
Winey [26] Varian OBI 125 1.6 CIRS Thorax Chamber/OSL 2.4e9.1
Marinello [27] Varian OBI 125 2 Rando TLD/Gafchromic 4.7e6.2
Tomic [29] Varian OBI (v1.4) 100 0.2 Rando head, chest, pelvis Gafchromic 0.1e4.7 (surface)
100 0.4
100 1.6
125 1.04
125 1.6
Tomic [30] Varian OBI (v1.4) 100 0.2 Rando head, chest, pelvis Gafchromic 0.03e2.8 (surface)
100 0.4
100 1.6
125 1.04
125 1.6
Hyer [31] Varian OBI (v1.4) 100 0.4 Male Anthro head, chest, pelvis Scintillator 0.2e2.8
110 0.4
125 1.04
Elekta XVI (v.4) 100 0.1 0.1e2.9
120 1.6
120 2.56
Palm [32] Varian OBI (v1.3) 125 0.4 Female Rando head, chest, pelvis TLD 8.7e13
125 2
Varian OBI (v1.4) 125 1.04 0.25e3.42
125 2
100 0.2
100 0.4
100 2
Cheng [33] Varian OBI 125 1.6 Female Rando head & pelvis TLD 1.3e9.4
100 1.6 0.4e3.0
124 1.04
Dufek [34] Varian OBI (v1.3) 125 264 (total) Rando head & pelvis TLD 0.01e1.66
Varian OBI (v1.4) 125 0.64 0.01e1.19
100 0.2
Elekta XVI 100 0.1 0.01e3.49
120 1.6
Halg [39] Varian OBI (v1.4) 125 2.0 Rando TLD 0.7e2.8
125 2.0 0.7e4.0
110 0.4 0.2e0.8
100 2.0 0.3e1.8
Varian TrueBeam (v1.0) 125 686.4 (total) 0.4e1.7
Elekta XVI (v4.2) 120 2.6 0.7e3.9
Giaddui [41] Elekta XVI (v4.5) 100 0.4 Rando head, chest, pelvis Gafchromic/OSL 0.02e5
100 0.4
120 0.32
120 1.6
Varian OBI (v1.5) 100 0.72 0.4e5.6
125 0.4
125 1.6
125 3.6
Alvarado [42] Varian OBI (v1.5) 110 0.4 Female Rando chest Gafchromic 0.8e1.0
Moon [43] Elekta XVI 120 1.6 Female Rando head, chest, pelvis Glass 0.2e3.0
Nobah [44] Varian OBI (v1.4) 100 0.4 Rando head, chest, pelvis Gafchromic 0.03e4.91
110 0.4
125 1.6
Varian TrueBeam 100 0.4 0.07e3.15
125 0.4
125 1.6
Megavoltage CBCT MU
Gayou [23] Siemens TBL 5, 8, 10, 15 Rando head & pelvis TLD/Radiographic ﬁlm 6.0e7.3 in HN (8 MU)
9.9e12.1 in Pelvis (15 MU)
10 Cylindrical (16 and 32 dia.) Chamber 7.9 & 9.2 in center
Morin [24] Siemens TBL 5, 9 Cylindrical Chamber/MOSFET Not reported
Isambert [28] Siemens TBL 5 Cylindrical Chamber 3.7
Rando TLD 3.7 (isocenter)
Quinn [36] Siemens TBL 8 Female Anthro TLD/MOSFET 0.1e4.5 on skin
Halg [39] Siemens TBL 3 Rando TLD 0.9e2.4
Table 2
Summary of CBCT dose measurements in/on patient.
Kilovoltage CBCT Manufacturer kVp mAs/acquisition Dosimeter Dose/fraction (cGy) & location
Islam [20] Elekta XVI 120 2 MOSFET 1.12e1.84 (skin)
Amer [21] Elekta XVI 100 0.1 TLD 0.12 (skin)
120 0.4 0.6e1.1 (skin)
130 1.2 2.2e3.5 (skin)
Walter [46] Elekta XVI 120 1 Chamber 1.72 (avg.) (rectum)
Wen [22] Varian OBI 125 2 TLD 2.3e6.1 (skin)
Jeng [47] Elekta XVI 120 1 TLD 2.86 (avg.) (rectum)
Marinello [27] Varian OBI 125 2 TLD 5.8e7.3 (skin, AP/PA)
3.4e4.5 (skin, lateral)
Table 3
Summary of CBCT beam data collection and simulation/modeling.
Kilovoltage CBCT System Beams Details
Ding [49] Varian OBI Single beam, half-fan, half-bowtie Beam data collection, MC simulation and veriﬁcation
Chow [58] Elekta XVI Single cassette, no ﬁlter Beam data collection, MC simulation and veriﬁcation
Spezi [50] Elekta XVI Multiple cassettes, no ﬁlter Beam data collection, MC simulation and veriﬁcation
Downes [51] Elekta XVI Multiple cassettes, bowtie Beam data collection, MC simulation and veriﬁcation
Ding [48] Varian OBI Multiple beams/ﬁlters Beam data collection, MC simulation and veriﬁcation
Alaei [52] Varian OBI Single beam, half-fan, half- bowtie Modeling in TPS and veriﬁcation
Deng [59] Varian OBI Half-fan, half-bowtie & Full-fan, full-bowtie Beam data collection, MC simulation and veriﬁcation
Deng [60] Varian OBI Half-fan, half-bowtie & Full-fan, full-bowtie Beam data collection, MC simulation and veriﬁcation
Alaei [53] Elekta XVI Multiple cassettes, no ﬁlter and bowtie Modeling in TPS and veriﬁcation
Dzierma [57] Siemens kView Two beam qualities Beam data collection, modeling in TPS and veriﬁcation
Megavoltage CBCT
Flynn [45] Siemens IBL IBL beam Beam data collection, modeling in TPS and veriﬁcation
Table 4
Summary of CBCT Monte Carlo dose calculations.
Manufacturer Acquisition
techniques per frame
Code used Dose type Source type Phantom type Dose summary
Chow [58] Elekta XVI 100, 120, 130,
140 kVp, unspeciﬁed
mAs
EGSnrc/BEAMnrc Medium Phase space Patient CT Table IV (organ doses)
Ding [49] Varian OBI 125 kVp, 2 mA s BEAMnrc/DOSXYZnrc Medium Phase Space RSVP phantom and
patient CT
Table I (organ doses)
Gu [61] N/A 125 kVp, 2 mA s -
6 MV 0.03 MU
MCNPX Medium X-ray Spectrum VIP Man phantom Table 5 (kV) Table 8
(MV)
Downes [51] Elekta XVI 120 kVp, 1.6 mA s EGSnrc/BEAMnrc Water Phase Space Phantoms and patient
CT
Figures 10e12 (organ
doses)
Walters [62] Varian OBI 125 kVp, 2 mA s BEAMnrc Medium Phase Space Voxelized human
phantoms
Table II (skeletal
doses)
Ding [63] Varian OBI 125 kVp, 2 mA s DOSXYZnrc Medium Phase Space Patient CT Table 1 (organ doses)
Ding [64] Varian OBI 125 kVp, 250 mA s
(total)
MCNPX Medium X-ray Spectrum Patient CT Table I (organ doses)
Ding [48] Varian OBI 100 kVp, 0.2, 0.4,
2 mA s; 125 kVp, 0.4,
1.04, 2 mA s
DOSXYZnrc Medium Phase Space Patient CT
Qiu [65] Varian OBI 125 kVp, unspeciﬁed
mAs
BEAMnrc/DOSXYZnrc Medium Full head Patient CT Tables 1 and 2 (organ
doses)
Spezi [66] Elekta XVI 100 kVp, 0.1 mA s;
120 kVp, 1.6 mA s
EGSnrc/BEAMnrc Medium Phase Space Patient CT Table 2 (organ doses)
Deng [59] Varian OBI 60, 80, 100, 125 kVp,
1.04, 1.6 mA s
EGS4/BEAM/MCSIM Medium Source Model Patient CT Table 2 (organ doses)
Deng [60] Varian OBI 60, 80, 100, 125 kVp,
1.04, 1.6 mA s
EGS4/BEAM/MCSIM Medium Source Model Patient CT Table 3 (pediatric
organ doses)
Qiu [67] Varian OBI 125 kVp, 1.04 mA s BEAMnrc/DOSXYZnrc Medium Full head Patient CT
Zhang [68] Varian OBI 100 kVp, 2 mA s;
125 kVp, 1.04 mA s
EGS4/BEAM/MCSIM Medium Source Model Patient CT
Ding [69] Varian OBI 100, 110, 125 kVp,
0.36e3.7 mA s
EGS4/BEAM/MCSIM Medium Source Model Patient CT
Son [70] Varian OBI 125 kVp, 2.0 &
0.4 mA s
BEAMnrc Medium Phase Space Patient CT
Montanari [72] Varian OBI 100 kVp 0.4 mA s;
125 kVp, 1.04,
2.0 mA s
gCTD Medium Source Model Phantoms and
patient CT
Tables 4e6 (organ
doses)
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Figure 2. Isodose distribution demonstrating imaging dose from 25 fractions of pelvic imaging for one patient using Elekta XVI pelvis imaging protocol (120 kVp, 1 mA s, 650
projections) and calculated using Pinnacle treatment planning system. (Reproduced with permission from Alaei et al. [78]).
P. Alaei, E. Spezi / Physica Medica 31 (2015) 647e658652computation [52,53,57,78]. Fig. 2 is an example of imaging dose
distribution in pelvis calculated by the TPS. Due to algorithm lim-
itations in this system and its applicability to Megavoltage beam
energies, this computation produces dose distributions which are
of reasonable accuracy in soft tissue and lung, but not in and around
bone mineral. Adding the dose distribution generated by different
quality beams is essentially summing the physical doses delivered
from Megavoltage and kilovoltage beams. Since there is currently
no accurate method to convert absorbed dose to effective dose for
different quality beams, all the doses reported in these publications
and this review are absorbed dose.
In addition to the use of treatment planning system and MC,
other methods have also been proposed to compute imaging dose.
One is a correction-based dose calculation algorithm [79e81]. This
algorithm overcomes the inaccuracy of convolution-based dose
calculation algorithms, due to not accounting for atomic number
changes in kilovoltage energy range, by introducing another
correction factor to account for these changes.Table 5
Summary of CBCT dose calculations performed by methods other than Monte Carlo.
Kilovoltage CBCT Manufacturer kVp mAs/acquisition
Alaei [52] Varian OBI 120 2
Alaei [53] Elekta XVI 100, 120 0.1, 0.25, 1, 1.6, 2.56
Alaei [78] Elekta XVI 100, 120 0.1, 1
Dzierma [57] Siemens kView 70, 121 0.5, 0.6, 1
Ding [49] Varian OBI N/A N/A
Hyer [82] Varian OBI 100, 110, 125 0.4, 1.04
Elekta XVI 100, 120 0.1, 1.6, 2.56
Pawlowski [80] Varian OBI N/A N/A
Megavoltage CBCT MU
Peng [73] Siemens TBL 9
Gayou [23] Siemens TBL 5, 8, 10, 15
Miften [54] Siemens TBL 15
Morin [55] Siemens TBL 5, 9
Isambert [28] Siemens TBL 5
Flynn [45] Siemens TBL & IBL
Beltran [77] Siemens TBL & IBL N/A
vanAntwerp [74] Siemens TBL 2, 4, 8
Akino [75] Siemens TBL 3, 5, 8, 15
Zabel-du Bois [76] Siemens TBL 6, 10
a Accuracy veriﬁed in phantom.
b Patient dose calculation.
c Imaging dose combined with treatment planning dose.
d Philips Medical Systems, Eindhoven, The Netherlands.
e ImPACT Group, St. George's Healthcare NHS Trust, London, UK.
f Elekta AB, Stockholm, Sweden.
g University of North Carolina, NC, US.
h Dosisoft, Cachan, France.
i DKFZ, Heidelberg, Germany.Another method extracts organ doses from CTDI values by
introducing an organ dose conversion coefﬁcient for clinical imag-
ing protocols used [82]. In yet another dose estimation method, MC
calculations have been used to calculate organ doses for different
cohorts of patients imaged using various clinical protocols. This data
has then been tabulated to be used to estimate organ doses for
patients imaged using the same protocols [83]. The rationale for this
dose estimation method is the relatively small variation of imaging
dose with patient size and isocenter position; hence the approach
taken is different than those attempting to calculate individualized
imaging dose and including it in the treatment plan.
All the non-Monte Carlo dose calculation methods are tabulated
in Table 5.
A few observations on CBCT dose calculations are warranted:
MV CBCT exhibits a dose gradient within the body because of the
partial arc image acquisition employed as seen in Fig. 3; hence for a
patient treated in supine position, the bulk of the dose is deposited
in the anterior part of the body.Phantom type Method Notes
Rando Pelvis Pinnacle TPSd a
Rando head, chest, pelvis Pinnacle TPS a
Patient Pinnacle TPS b, c
Rando head, chest, pelvis Pinnacle TPS a, b
N/A Correction-based algorithm a
CTDI/Anthro CTDI value and ImPACTe dose calculator a
N/A Correction-based algorithm a, b
Patient Pinnacle TPS b
Cylindrical/Rando Xio TPSf a
Patient Xio TPS b, c
Cylindrical/patient Pinnacle TPS a, b, c
Cylindrical/Rando/
patient
ISOgray TPSh a, b
Cylindrical/patient Pinnacle TPS a, b
Solid water/patient PlanUNC TPSg a, b
Patient Pinnacle TPS b
I'mRT phantom/patient Xio TPS a, b, c
Patient VOXELPLAN TPSi b
Figure 3. Distribution of dose deposited in the pelvis by a single fraction of MV CBCT
imaging for a prostate patient, with 10 cGy at isocenter. The isodose lines are labeled in
cGy. (Reproduced with permission from Miften et al. [54]).
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maximum dose on the skinwith enhanced dose absorption in bone
mineral due to predominance of photoelectric effect. Fig 4 is an
example of an MC-calculated kV CBCT dose distribution.
Patient size does play a role in the imaging dose from kV CBCT
with larger patients receiving lower dose to the isocenter and in-
ternal organs, but not to the skin [78]. This can be described as a
correlation between body mass index (BMI) and organ doses,
especially in pelvic imaging. This correlation is weak in the case of
Megavoltage imaging [74] but stronger for kilovoltage ones [78].
The correlation between patient size and imaging dose translates
into increased dose to pediatric patients when adult imaging
techniques are employed. This is further discussed in the section on
dose reduction in pediatric cases below.
Peripheral dose from CBCT imaging
As in any other application of x rays, there is always dose
deposition outside the volume of interest, with its magnitude
depending on the amount of leakage and scatter. The peripheral
dose from imaging could be of interest when there is a need to
assess and/or minimize the dose outside the treatment volume, for
example when the patient has a Cardiac Implantable Electronic
Device (CIED).
Although many have pointed to out-of-ﬁeld dose from CBCT
imaging, few publications have exclusively focused on the periph-
eral dose. In one such article, Perks et al. [84] measured the pe-
ripheral dose from kV CBCT and compared it to that from radiationFigure 4. Patient dose from Elekta XVI CBCT pelvis scan simulated using the M10
collimator and F1 (bowtie) ﬁlter. (Reproduced with permission from Downes et al.
[51]).therapy treatment itself by surface and internal phantom mea-
surements. They concluded that peripheral doses from imaging, at
measurement points of equal distance from the central axis, are of
the same order of magnitude as those of an IMRT treatment. Qiu
et al. [67] also investigated the magnitude of peripheral dose from
kV CBCT as well as IMRT delivery and linac head leakage using MC
simulation and concluded that dose to peripheral organs from CBCT
is of the same order of magnitude as linac leakage and one order of
magnitude lower than IMRT or RapidArc scatter dose.
In both of the above studies the imaged volume is larger than
the treated one and the CBCT dose at a few centimeters from the
edge of imaged volume drops to fractions of cGy. In addition, both
studies utilized the pelvic (high dose) imaging hence the peripheral
dose could be substantially less if a low dose setting is used. In
another study, Jia et al. [85] measured the peripheral dose from a
MV CBCT system and concluded that the magnitude of its periph-
eral dose is similar to that of kV CBCT imaging, and that it increases
with use of higher dose imaging.CBCT imaging dose reduction
There are methods to reduce the imaging dose such as reducing
the number of frames acquired and/or decreasing the current-time
(mAs) settings for a particular acquisition in kilovoltage imaging.
These reductions, however, may compromise the image quality.
There are several studies examining this such as those by Sykes
et al. [18], Ding et al. [86] and Alvarado et al. [42] in which the
authors reduced the number of image acquisitions, adjusted the
start/stop angles of the imaging source, reduced scan length, and
used low-dose (or reduced mAs) protocols to image instead of
standard high-dose ones. Another method to reduce imaging dose
proposed by Roxby et al. [87] introduces a Copper ﬁlter to the beam
hence increasing its half value layer and decreasing the delivered
dose. More recently, Grelewicz and Dzierma [88] proposed a
method to reduce kV imaging dose by combining MV and kV in-
verse planning using MC. As for the megavoltage beams, the use of
low accelerating potential for the imaging beam and a Carbon
target, the IBL, has reduced the dose commonly encountered when
using the 6 MV therapeutic beam for imaging [56]. Many of the
above methods can easily be implemented in the clinic.Dose reduction in pediatric cases
Imaging dose reduction is of greater importance in children than
adults due to several factors. First is the increased susceptibility of
children to radiation-induced secondary malignancies. The second
factor is the increased absorption of kilovoltage beams in bone
mineral, which could have a detrimental effect on the bone growth
in children. And the third is that using standard CBCT imaging
protocols often result in unnecessarily excessive dose to children
due to their smaller body sizes.
In a Monte Carlo study, Ding and Coffey [63] showed that the
pediatric imaging dose delivered to several organs is up to twice
that of adult imaging. This ratio is higher for dose to the bone.
Zhang et al. [68] evaluated kV CBCT doses to pediatric patients of
various sizes and noted a three-fold variation of mean dose to fe-
murs in their study population due to patient size differences.
Therefore, imaging dose to patients of smaller size is enhanced
should the same imaging protocols as adults are utilized. In another
Monte Carlo study, Deng et al. [59] calculated kV CBCT imaging
dose to pediatric cancer patients and concluded that critical
structures in children receive doses larger by a factor of 2e3
compared to adult ones (Fig. 5). All of these studies verify the
correlation between BMI and organ doses discussed previously.
Figure 5. Monte Carlo-calculated dose distributions of 125-kV half-fan CBCT with pelvis protocol on a pediatric patient with abdominal lesion (aec). (Reproduced with permission
from Deng et al. [59]).
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patients, dose reduction methods should be employed to manage
these cases. One method to achieve this is utilizing protocols used
for adult head and neck imaging for body imaging of pediatric
patients (essentially decreasing the current-time product), or
reducing the number of frames [89]. Using these methods, the
imaging dose to patient is shown to decrease by several fold as
shown in Fig. 6. Other potential dose reduction methods include
modifying start/stop angles of imaging beams both to reduce the
dose and to avoid critical structures. All of these methods could be
used providing the image quality is not compromised.
Estimation of effective dose from CBCT imaging
The AAPM Task Group 75 report [5] emphasized the use of
effective dose when evaluating patient exposure to imaging doses.
Several studies reported on the effective doses from kilovoltage
CBCT [6,31,33,34,39,43,90]. In all these cases, the absorbed dose
was measured in an anthropomorphic phantom and converted to
effective dose using the tissue weighting factors obtained fromFigure 6. The TPS-calculated dose distribution from 11 daily CBCT imaging using: a) the sta
neck imaging demonstrating an 18-fold reduction in dose.International Commission on Radiological Protection (ICRP) reports
60 and 103 [91,92]. They reported effective dose values within a
wide range of 1.1e24 mSv for trunk and 0.04e9.4 mSv for head and
neck imaging, per fraction. In another study, Gu et al. [61]
computed effective doses for both kV and MV imaging using
Monte Carlo-calculated absorbed doses and ICRP 103 weighting
factors and reported values within the above range.
The wide variation of reported values can be explained based on
the anatomical site, measured dose, relative tissue weighting fac-
tors used, imaging protocol (low vs. standard dose), and make of
the imager which dictates the extent of the volume imaged, as well
as use of bowtie ﬁlter. The version of the hardware/software uti-
lized also affects the outcome, with newer versions tending to
optimize image quality and size, which contributes to reduce the
concomitant dose. In general, low dose imaging protocols
employed in head and neck imaging result in effective doses less
than 2 mSv. Effective doses of up to 24 mSv have been reported for
standard imaging protocols. The use of effective dose, however, is
limited because it cannot be easily added to the absorbed dose to
estimate total dose delivered to patient.ndard protocol used for pelvic imaging, and b) the standard protocol used for head and
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Computed Tomography Dose Index (CTDI) has been an estab-
lished quantitative tool for dosemeasurements of CT scanners since
its introduction in 1981 [93]. The CTDI measurements are made in
polymethyl methacrylate (PMMA) cylinders of 15 cm in length and
16 and 32 cm in diameter (mimicking head and body) using 10 cm-
long ionization chambers. The usage of the CTDI, however, has
become the subject of debate in recent years with the advent of
multi-slice detectors with scan widths greater than 10 cm which
result in primary radiation not registered completely by the
chamber [9]. The International Electrotechnical Commission (IEC)
[94], AAPM [95], and International Atomic Energy Agency (IAEA)
[96] have proposed new and different approaches to measure CTDI
which are beyond the scope of this review. The publications
reviewed here use the traditional CTDI measurement methodology
expanded to CBCT, even though the same problem with limited
chamber size exists as CBCT scanwidths are often more than 10 cm
[18,21,25,33,46,82,97,98]. In addition, CBCT scan widths may be
longer than the 15 cm phantom length, hence some groups have
stacked up two or three phantoms to cover the entire length of the
CBCT scan [21,32]. There has also been a new terminology “Cone
Beam Dose Index” or CBDI proposed for CTDI measurements on
CBCT systems [21,25,82].
The reported measured CTDI values for both Varian OBI and
Elekta XVI systems are summarized in Table 6. The values tabulated
here are normalized to the current-time product, i.e. divided by
100 mA s [CTDIw (mGy/100 mA s)]. Only the values obtained using
the standard CTDI phantoms and 10 cm ion chamber are included in
this table. A review of this data indicates obvious variations, which
are due to differences in technique, cassette/ﬁeld size, and bowtie
ﬁlter with an average value of 4.6 (±2.6) mGy. The average value for
headmeasurements is 5.8 (±3.1)mGyand for body ones is 3.9 (±2.1)
mGy. The values reported for Varian OBI are higher on average than
those for Elekta XVI (5.6 vs. 3.3 mGy); although this cannot be used
to draw conclusions on the relative dose output of the two systems
as the data spans multiple versions of these systems.Table 6
Summary of CTDIw measurements for CBCT systems.
Manufacturer
(Version if speciﬁed)
kVp mAs/acquisition
Sykes [18] Elekta XVI
(v3.1)
130 0.56
100 0.25
Walter [46] Elekta XVI 120 1
Song [97] a Elekta XVI 100 0.1
120 1
120 1
120 1.6
Varian OBI 125 0.4
125 0.4
125 0.4
125 0.4
125 2
125 2
Osei [25] Varian OBI 125 1
125 1
125 1
125 1
Hyer [82] Elekta XVI
(v4.0)
100 0.1
120 1.6
120 2.56
Varian OBI
(v1.4)
100 0.4
110 0.4
125 1.04
Falco [98] Elekta XVI
(v3.5)
120 1.6
a 18 and 30 cm phantoms used in this study.A comparison of the reported cone beam CTDIw values in Table 6
with those reported for diagnostic fan beam CT scanners indicates
generally lower values for CBCT scans than fan-beam CT ones. For
example, Lee at al [99]. provided a database of normalized CTDIw
values for all major manufacturers and reported CTDIw values be-
tween 7 and 24 mGy/100 mA s for the 120 kVp beam, which is
higher on average than that for CBCT as tabulated in Table 6. The
reason for this difference is two-fold: The ﬁltration used is CBCT
systems is different than that in diagnostic CT units, and the photon
ﬂuence in CBCT is smaller than that in fan beam CT under similar
kVp andmAs because the longitudinal proﬁle in a CT beam does not
drop-off as rapidly as that in CBCT.
Conclusions
Cone beam CT has become a standard imaging tool for patient
localization in radiation therapy. Imaging dose from CBCT has
traditionally been ignored as its magnitude has been deemed
negligible comparing to therapeutic dose used to treat patients.
However the daily use of this imaging modality prompted another
look into the necessity and efﬁcacy ofmeasuring, documenting, and
accounting for imaging dose. This clearly becomes an issue of
concern if the magnitude of the imaging dose is signiﬁcant
compared to the therapeutic one. This review summarized the ef-
forts made in measurement and calculation of the additional dose
from this imaging modality and its potential effect on the overall
dose delivered to patients during their course of radiation therapy
treatment.
Since the onset of the use of CBCT units, there have been im-
provements by the manufacturers in reducing imaging dose, with
the newer systems generally delivering lower dose than the older
ones. Current CBCT systems use different methods, including
collimator cassettes and ﬁeld size-deﬁning blades, to limit the
extent of the x-ray beam. This has an effect on the total volume of
the scan and consequently on the imaging dose to healthy tissues.
The use of bowtie ﬁlters affects beam quality and often results in
lower skin doses. Moreover, post-processing techniques are oftenCTDI phantom
(Head or body)
CTDIw
(mGy/100 mA s)
Radiation ﬁeld/ﬁlter
Head 8.5 S20/no ﬁlter
Head 4.2 S20/no ﬁlter
Body 2.9 M10
Head 2.8 S20/no ﬁlter
Body 2.8 L20/no ﬁlter
Body 3.7 M20/no ﬁlter
Body 3.4 M10/no ﬁlter
Head 6.7 Full-fan/full-bowtie
Body 4.4 Half-fan/half-bowtie
Head 11.5 Full-fan/no ﬁlter
Body 7.5 Half-fan/no ﬁlter
Head 6.6 Full-bowtie/full-fan
Body 4.3 Half-bowtie/half-fan
Body 3.2 Full-fan/full-bowtie
Body 3.9 Half-fan/half-bowtie
Body 8.3 Full-fan/no ﬁlter
Body 7.5 Half-fan/no ﬁlter
Head 2.7 S20/no ﬁlter
Body 1.6 M20/bowtie
Body 1.5 M10/bowtie
Head 3.6 Full-fan/full-bowtie
Body 2.3 Half-fan/half-bowtie
Body 3.2 Half-fan/half-bowtie
Body 2.4 M10/bowtie
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of the dose from the CBCT system is directly related to the current-
time product used in the image acquisition protocol. This value is
usually pre-set within each clinical protocol but can be changed by
the user. The size of the patient also affects the magnitude of the
dose delivered at depth, especially for kilovoltage beams. A direct
correlation has been observed between the patient size (indicated
by BMI) and organ dose from kilovoltage imaging, especially since
CBCT systems do not use automatic exposure control (AEC)
adjustment, which is common in diagnostic imaging units. Equip-
ping CBCT systems with AEC would help reducing imaging dose. In
addition, there are methods that can be utilized by the user to
reduce imaging dose including: (a) adjusting the start/stop angles
of the x-ray source, potentially avoiding radio-sensitive organs, (b)
reducing scan length by using smaller cassettes or ﬁeld sizes, (c)
using low-dose protocols to image, providing an acceptable image
can be acquired.
If a high dose protocol is employed on a daily basis, it is possible
to deliver, over the course of treatment, imaging dose to patient
equal to one therapy dose fraction. In this case, it may be warranted
to include the imaging dose in the planning process. It has been
shown that this approach is feasible and that including imaging
dose during plan optimization reduces the overall dose delivered to
patient [54,78,88]. This, however, is not a trivial task and requires
either use of Monte Carlo or commissioning of imaging beams in
treatment planning systems. Currently, none of the commercially
available systems are capable of computing dose from kilovoltage
imaging beams. The capability of accounting for imaging dose
added to therapeutic dose in IGRT should be implemented in
commercial treatment planning systems to allow for full person-
alization of dose optimization.
As for the magnitude of the dose, as reported in this work the
overall dose delivered fromkV CBCT ranges from a fraction of one to
4e5 cGy to internal organs, with values of up to 7 cGy reported for
skin dose. The dose varies depending on the protocol used, with
protocols designed for head and neck imaging delivering doses at
the low end of this range, and those designed for pelvic imaging
delivering doses at the high end of it. The published data is often
subject to large variations because of the differences in methods
and phantoms used for imaging dose calculations. For example,
AAPM TG-179 states that the imaging dose ranges from 0.2 to 2 cGy
[100]. This range, however, is not entirely accurate as one can derive
from Tables 1 and 2 of this review. MV CBCT, using the 6 MV beam
(TBL), often delivers higher doses than kV CBCT, with reported
values of over 10 cGy per fraction for high dose protocols, and ac-
counting for this additional dose should be of high importance
when a frequent CBCT scan approach is used. TheMV CBCT dose can
easily be calculated by the treatment planning systems and
accounted for in patient treatment plans as shown in several
publications [54,55,75].
The peripheral dose from CBCT has been found to be at the same
order of magnitude or smaller than that from leakage and scattered
radiation from therapeutic beams. This could only be of concern
when a radiosensitive electronic device is exposed to the imaging
beam. Effective dose can be used to describe imaging dose with the
limitation that it cannot be easily added to the absorbed dose,
which is the common descriptor of dose in radiation therapy.
The CTDI values measured for CBCT systems can be used as an
indicator of the average dose delivered by the unit by delivering the
x-rays to a cylindrical phantom in the central region of a scan. Since
CTDI requires the use of a standard phantom for measurement, it
can easily be compared between various manufacturers and the
data tabulated in this review show the full extent of variations in
dose due to different CBCT systems and settings. Due to the limi-
tations of measuring CTDI values for CBCT systems, such as thelimited length of the ion chamber and the phantom compared to
the dimensions of the CBCT x-ray beam, it may be necessary to
follow the recommendations of AAPM [95] and IEC [94], or more
recently IAEA [96] on CT dosimetry of wide cone beam scanners
and the adoption of the CTDI300 concept.
This review demonstrates that there is increasing awareness
and strong interest in the evaluation of the concomitant dose
from CBCT. With image guidance becoming a very important part
of the radiotherapy treatment pathway of each patient, and with
treatment adaptation based on a dose re-calculation on the
actual patient treatment position becoming increasingly possible,
it is very important that we implement the tools needed to
control and manage the potentially detrimental effects of addi-
tional dose from on-board imaging devices. We hope that the
data systematically collected in this work will provide useful
reference material for clinicians and scientists to use in daily
clinical practice and possibly accelerate the clinical imple-
mentation of solutions that are currently only available in the
research environment.References
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